Pharmaceutical Technology Europe
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Cecil Nick
Advertisement
Cecil Nick is Vice President, Biotechnology, at PAREXEL Consulting.
Articles by Cecil Nick
Advertisement
Latest Updated Articles
- Clinical And Cost Considerations Of Developing A Biosimilar
September 1st 2010
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
2
PharmTech Weekly Roundup—June 5, 2026
3
EMA Collaborates with African Regulators on Ebola Treatments
4
CPHI Americas: How FDA Instability Is Reshaping Pharmaceutical Development
5